Revance Therapeutics (RVNC) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Revance Reports Third Quarter 2019 Financial Results, Provides Corporate Update
November 4, 2019 4:10 PM ESTConference call and webcast today at 4:30 p.m. ET
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today reported financial results for the quarter ended September 30, 2019, and provided a corporate update.
Third Quarter 2019 and Subsequent Updates
Board Appointed Mark J. Foley as President and Chief Executive Officer (CEO). In October, Revance announced that Mark Foley had assumed the role of President and CEO,... More